Expression of connective tissue growth factor in cartilaginous tumors

Toshihiko Shakunaga, Toshihumi Ozaki, Nobuya Ohara, Koji Asaumi, Takeshi Doi, Keiichiro Nishida, Akira Kawai, Tohru Nakanishi, Masaharu Takigawa, Hajime Inoue

Research output: Contribution to journalArticle

84 Citations (Scopus)

Abstract

BACKGROUND. Connective tissue growth factor (CTGF) predominantly is expressed in hypertrophic chondrocytes and its specific receptors are demonstrated on chondrocytic cells. Therefore, CTGF may be involved in the proliferation and/or differentiation of cartilage cells. In the current study, CTGF expression was examined both in chondrosarcoma and enchondroma to clarify the relation between the expression of CTGF and the grade of malignancy. METHODS. The expression of CTGF and proliferating cell nuclear antigen (PCNA) were analyzed immunohistochemically in 34 cartilaginous tumor specimens. Eighteen tumors were determined to be chondrosarcoma including 8 Grade 1 tumors, 6 Grade 2 tumors, and 4 Grade 3 tumors. The percentage of CTGF positive and PCNA positive cells was quantified using at least 500 cells. RESULTS. CTGF was expressed in 70.1% of enchondroma cells, 84.0% of Grade 1 chondrosarcoma cells, 53.7% of Grade 2 tumor cells, and 26.8% of Grade 3 tumor cells (ρ = -0.501; P = 0.0053). In chondrosarcoma cases, CTGF expression was correlated closely with tumor grade (ρ = -0.920; P = 0.0001). There was a strong correlation between PCNA expression and tumor grade (ρ = 0.907; P <0.0001) and a strong negative correlation between CTGF and PCNA expression (ρ = -0.493; P = 0.0061). In chondrosarcoma cases, patients with high expression of CTGF (≥ 30%) showed higher overall survival compared with those with low expression (<30%) (P = 0.004). CONCLUSIONS. The current study revealed a correlation between the histologic grade of chondrosarcoma and prognosis, and the concomitant association between CTGF immunostaining and tumor grade and prognosis. Therefore, immunohistochemical staining with CTGF is a useful procedure for assessing the tumor grade anti clinical course in patients with chondrosarcoma. (C) 2000 American Cancer Society.

Original languageEnglish
Pages (from-to)1466-1473
Number of pages8
JournalCancer
Volume89
Issue number7
DOIs
Publication statusPublished - Oct 1 2000

Fingerprint

Connective Tissue Growth Factor
Chondrosarcoma
Neoplasms
Proliferating Cell Nuclear Antigen
Chondroma
Chondrocytes
Cartilage
Cell Differentiation

Keywords

  • Chondrosarcoma
  • Connective tissue growth factor (CTGF)
  • Enchondroma
  • Immunohistochemistry
  • Proliferating cell nuclear antigen (PCNA)

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Expression of connective tissue growth factor in cartilaginous tumors. / Shakunaga, Toshihiko; Ozaki, Toshihumi; Ohara, Nobuya; Asaumi, Koji; Doi, Takeshi; Nishida, Keiichiro; Kawai, Akira; Nakanishi, Tohru; Takigawa, Masaharu; Inoue, Hajime.

In: Cancer, Vol. 89, No. 7, 01.10.2000, p. 1466-1473.

Research output: Contribution to journalArticle

Shakunaga, Toshihiko ; Ozaki, Toshihumi ; Ohara, Nobuya ; Asaumi, Koji ; Doi, Takeshi ; Nishida, Keiichiro ; Kawai, Akira ; Nakanishi, Tohru ; Takigawa, Masaharu ; Inoue, Hajime. / Expression of connective tissue growth factor in cartilaginous tumors. In: Cancer. 2000 ; Vol. 89, No. 7. pp. 1466-1473.
@article{2b9ece5385ec425e8c35efdf3a88b1ea,
title = "Expression of connective tissue growth factor in cartilaginous tumors",
abstract = "BACKGROUND. Connective tissue growth factor (CTGF) predominantly is expressed in hypertrophic chondrocytes and its specific receptors are demonstrated on chondrocytic cells. Therefore, CTGF may be involved in the proliferation and/or differentiation of cartilage cells. In the current study, CTGF expression was examined both in chondrosarcoma and enchondroma to clarify the relation between the expression of CTGF and the grade of malignancy. METHODS. The expression of CTGF and proliferating cell nuclear antigen (PCNA) were analyzed immunohistochemically in 34 cartilaginous tumor specimens. Eighteen tumors were determined to be chondrosarcoma including 8 Grade 1 tumors, 6 Grade 2 tumors, and 4 Grade 3 tumors. The percentage of CTGF positive and PCNA positive cells was quantified using at least 500 cells. RESULTS. CTGF was expressed in 70.1{\%} of enchondroma cells, 84.0{\%} of Grade 1 chondrosarcoma cells, 53.7{\%} of Grade 2 tumor cells, and 26.8{\%} of Grade 3 tumor cells (ρ = -0.501; P = 0.0053). In chondrosarcoma cases, CTGF expression was correlated closely with tumor grade (ρ = -0.920; P = 0.0001). There was a strong correlation between PCNA expression and tumor grade (ρ = 0.907; P <0.0001) and a strong negative correlation between CTGF and PCNA expression (ρ = -0.493; P = 0.0061). In chondrosarcoma cases, patients with high expression of CTGF (≥ 30{\%}) showed higher overall survival compared with those with low expression (<30{\%}) (P = 0.004). CONCLUSIONS. The current study revealed a correlation between the histologic grade of chondrosarcoma and prognosis, and the concomitant association between CTGF immunostaining and tumor grade and prognosis. Therefore, immunohistochemical staining with CTGF is a useful procedure for assessing the tumor grade anti clinical course in patients with chondrosarcoma. (C) 2000 American Cancer Society.",
keywords = "Chondrosarcoma, Connective tissue growth factor (CTGF), Enchondroma, Immunohistochemistry, Proliferating cell nuclear antigen (PCNA)",
author = "Toshihiko Shakunaga and Toshihumi Ozaki and Nobuya Ohara and Koji Asaumi and Takeshi Doi and Keiichiro Nishida and Akira Kawai and Tohru Nakanishi and Masaharu Takigawa and Hajime Inoue",
year = "2000",
month = "10",
day = "1",
doi = "10.1002/1097-0142(20001001)89:7<1466::AID-CNCR8>3.0.CO;2-G",
language = "English",
volume = "89",
pages = "1466--1473",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "7",

}

TY - JOUR

T1 - Expression of connective tissue growth factor in cartilaginous tumors

AU - Shakunaga, Toshihiko

AU - Ozaki, Toshihumi

AU - Ohara, Nobuya

AU - Asaumi, Koji

AU - Doi, Takeshi

AU - Nishida, Keiichiro

AU - Kawai, Akira

AU - Nakanishi, Tohru

AU - Takigawa, Masaharu

AU - Inoue, Hajime

PY - 2000/10/1

Y1 - 2000/10/1

N2 - BACKGROUND. Connective tissue growth factor (CTGF) predominantly is expressed in hypertrophic chondrocytes and its specific receptors are demonstrated on chondrocytic cells. Therefore, CTGF may be involved in the proliferation and/or differentiation of cartilage cells. In the current study, CTGF expression was examined both in chondrosarcoma and enchondroma to clarify the relation between the expression of CTGF and the grade of malignancy. METHODS. The expression of CTGF and proliferating cell nuclear antigen (PCNA) were analyzed immunohistochemically in 34 cartilaginous tumor specimens. Eighteen tumors were determined to be chondrosarcoma including 8 Grade 1 tumors, 6 Grade 2 tumors, and 4 Grade 3 tumors. The percentage of CTGF positive and PCNA positive cells was quantified using at least 500 cells. RESULTS. CTGF was expressed in 70.1% of enchondroma cells, 84.0% of Grade 1 chondrosarcoma cells, 53.7% of Grade 2 tumor cells, and 26.8% of Grade 3 tumor cells (ρ = -0.501; P = 0.0053). In chondrosarcoma cases, CTGF expression was correlated closely with tumor grade (ρ = -0.920; P = 0.0001). There was a strong correlation between PCNA expression and tumor grade (ρ = 0.907; P <0.0001) and a strong negative correlation between CTGF and PCNA expression (ρ = -0.493; P = 0.0061). In chondrosarcoma cases, patients with high expression of CTGF (≥ 30%) showed higher overall survival compared with those with low expression (<30%) (P = 0.004). CONCLUSIONS. The current study revealed a correlation between the histologic grade of chondrosarcoma and prognosis, and the concomitant association between CTGF immunostaining and tumor grade and prognosis. Therefore, immunohistochemical staining with CTGF is a useful procedure for assessing the tumor grade anti clinical course in patients with chondrosarcoma. (C) 2000 American Cancer Society.

AB - BACKGROUND. Connective tissue growth factor (CTGF) predominantly is expressed in hypertrophic chondrocytes and its specific receptors are demonstrated on chondrocytic cells. Therefore, CTGF may be involved in the proliferation and/or differentiation of cartilage cells. In the current study, CTGF expression was examined both in chondrosarcoma and enchondroma to clarify the relation between the expression of CTGF and the grade of malignancy. METHODS. The expression of CTGF and proliferating cell nuclear antigen (PCNA) were analyzed immunohistochemically in 34 cartilaginous tumor specimens. Eighteen tumors were determined to be chondrosarcoma including 8 Grade 1 tumors, 6 Grade 2 tumors, and 4 Grade 3 tumors. The percentage of CTGF positive and PCNA positive cells was quantified using at least 500 cells. RESULTS. CTGF was expressed in 70.1% of enchondroma cells, 84.0% of Grade 1 chondrosarcoma cells, 53.7% of Grade 2 tumor cells, and 26.8% of Grade 3 tumor cells (ρ = -0.501; P = 0.0053). In chondrosarcoma cases, CTGF expression was correlated closely with tumor grade (ρ = -0.920; P = 0.0001). There was a strong correlation between PCNA expression and tumor grade (ρ = 0.907; P <0.0001) and a strong negative correlation between CTGF and PCNA expression (ρ = -0.493; P = 0.0061). In chondrosarcoma cases, patients with high expression of CTGF (≥ 30%) showed higher overall survival compared with those with low expression (<30%) (P = 0.004). CONCLUSIONS. The current study revealed a correlation between the histologic grade of chondrosarcoma and prognosis, and the concomitant association between CTGF immunostaining and tumor grade and prognosis. Therefore, immunohistochemical staining with CTGF is a useful procedure for assessing the tumor grade anti clinical course in patients with chondrosarcoma. (C) 2000 American Cancer Society.

KW - Chondrosarcoma

KW - Connective tissue growth factor (CTGF)

KW - Enchondroma

KW - Immunohistochemistry

KW - Proliferating cell nuclear antigen (PCNA)

UR - http://www.scopus.com/inward/record.url?scp=0034306881&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034306881&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(20001001)89:7<1466::AID-CNCR8>3.0.CO;2-G

DO - 10.1002/1097-0142(20001001)89:7<1466::AID-CNCR8>3.0.CO;2-G

M3 - Article

C2 - 11013359

AN - SCOPUS:0034306881

VL - 89

SP - 1466

EP - 1473

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 7

ER -